Back to top
more

Lannett Co Inc (LCI)

(Delayed Data from NYSE)

$8.54 USD

8.54
1,487,457

+0.70 (8.93%)

Updated May 3, 2019 04:00 PM ET

After-Market: $8.54 (%) 5:22 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[LCI]

Reports for Purchase

Showing records 361 - 380 ( 421 total )

Industry: Medical - Drugs

Record: 361

02/07/2014

Company Report

Pages: 6

FY2Q14 - Modest Beat, Big Raise; PT to $40

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 362

02/07/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 363

01/24/2014

Company Report

Pages: 4

Suspending coverage on Lannett Company

Provider: STONEGATE CAPITAL MARKETS

Analyst: TRANG D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 364

01/22/2014

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 365

01/21/2014

Company Report

Pages: 4

Digoxin Still a Good Market, but One More Player

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 366

01/21/2014

Company Report

Pages: 4

Levo Monthly Data (December) In-Line to Ahead of Expectations

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 367

01/21/2014

Company Report

Pages: 4

Digoxin Tracking Ahead of Forecasts

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 368

12/17/2013

Daily Note

Pages: 4

Digoxin Monthly Data Continues to Surpass Targets

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 369

12/17/2013

Daily Note

Pages: 4

Levo Monthly Data (November) Matches Expectations

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 370

12/17/2013

Daily Note

Pages: 3

MORNING SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 371

11/18/2013

Company Report

Pages: 4

Levo Data Matches Expectations in October

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 372

11/18/2013

Company Report

Pages: 4

Digoxin Breaking Out in October Monthly Data

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 373

11/18/2013

Daily Note

Pages: 3

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 374

11/12/2013

Company Report

Pages: 12

Beating expectations as it raises the bar

Provider: STONEGATE CAPITAL MARKETS

Analyst: TRANG D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 375

11/08/2013

Daily Note

Pages: 4

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 376

11/08/2013

Company Report

Pages: 6

Trends Topping Already Bullish Expectations; PT to $34

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 377

10/31/2013

Daily Note

Pages: 4

MID-DAY SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 378

10/31/2013

Company Report

Pages: 5

Preliminary 1Q14 #''s Indicate Upside

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 379

10/18/2013

Daily Note

Pages: 3

MORNING CALL SUMMARY

Provider: Roth Capital Partners, Inc.

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Drugs

Record: 380

10/18/2013

Company Report

Pages: 4

Prescription Data Supports Levo Pricing Power

Provider: Roth Capital Partners, Inc.

Analyst: HENRY S

Price: 10.00

Research Provided by a Third Party
// eof